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Abstract: The development of novel bioartificial 
nerve grafts which release soluble therapeutic 
agents, shows great promises guiding the extension 
of the injured axons and optimizing and improving 
the degree and specificity of neural outgrowth. The 
TGF-β family cytokines are polypeptides involved in 
pathogenesis of neuropathies during nerve lesion. In 
particular, studies carried out on TGF-β1 have 
demonstrated its key-role as a humoral stimulus in 
scar formation. The use of neutralising antibodies to 
this pro-fibrotic factor, incorporated and released by 
medical devices, could be potentially useful to get 
improved results in nerve repair. The aim of this 
study was to characterise the uptake and release of 
antibodies, structurally no different from the anti-
TGFβ1 specific ones, by innovative constructs based 
on the use of biodegradable and biocompatible 
compounds with which to support and improve 
peripheral nerve repair.   
  
Introduction 
 
Nerves subjected to mechanical, thermal, chemical, 
or ischemic insults exhibit a regenerative potential, but, 
in the absence of surgical reconnection, the recovery of 
function following a transection or gap injury to a nerve 
is negligible. The separation between the nerve ends 
precludes sprouting axons from finding the distal stump 
and a variety of cellular and humoral events including 
the inflammatory and scarring response are triggered 
promoting the growth of connective tissue at the injury 
site which acts as a physical barrier to neurite 
elongation. This results in the formation of a neuroma, a 
dense, irregular tangle of axons which can cause painful 
sensations [1]. The use of biodegradable medical 
devices to improve the repair of injured human nerves 
can be useful to establish a direct, unbroken path 
between the proximal and distal stumps; to avoid scar 
tissue invasion into the regenerating environment; to 
actively promote by contact guidance, the alignment and 
movement of the elongating neuritis; to avoid tensions, 
which are known to stimulate the inflammation process 
and fibrosis, and that can arise in case of extensive 
deficit, or because of the formation of adhesions 
between repair and connective tissue; to inhibit the 
synthesis of pro-fibrotic factors by the release of 
therapeutic agents [1,  2, 3, 4, 5].  
The cytokine Transforming Growth Factor-β1 
(TGF-β1), that is expressed both in peripheral and 
central nervous injuries, plays a pivotal role in the 
regulation of the immune response and inflammation 
[6]. It has a multiple role acting as a chemotactic and 
pro-fibrotic agent enhancing the production of the 
extracellular matrix components and its neutralisation 
by specific antibodies (Ab) has shown to be effective to 
get improved results in the repair of nerve injuries [7, 
8].  
This study, as a preliminary work, focuses on the in 
vitro characterisation of the absorption and release 
kinetics of a general monoclonal IgG by medical 
devices based on natural materials which could be 
potentially used in vivo as controlled delivery systems 
and nerve guidance grafts [9, 10, 11]. More specifically, 
constructs made of an inner fibronectin (FN) mat of 
novel composition and of an outer HYAFF 11 tube 
(benzyl ester of the hyaluronic acid) were used to carry 
out the experiments. FN is an extracellular matrix 
glycoprotein involved in many aspects of wound 
healing [12] and FN based biomaterials [13, 14, 15] has 
been used to actively support nerve growth representing 
the most widely tested forms of contact guidance repair 
template [16, 17, 18]. Hyaluronan is naturally present at 
tissue interfaces and joints as a soft tissue lubricant; it is 
involved in the prevention of mechanical adhesion 
between connective tissue surfaces [19] and its benzyl 
ester derivative has already shown to be of efficacy for 
promoting tissue repair [20, 21].  
 
Materials and Methods 
 
To carry out the experimental work, as a preliminary 
study, a commercial R-Phycoerythrin labelled Goat 
Anti-Mouse IgG (whole molecule), produced by Sigma 
Aldrich Italia (Product number: P9287) was used. This 
Ab is structurally no different from the specific anti-
TGFβ1 one and the molecular weight is equivalent.  
The IgG tracing in solution was performed by 
spectrofluorimetry by means of a Perkin Elmer LS-50B 
Luminescence Spectrometer (Windows NT based 
software from Perkin Elmer).  
The analyses were performed by means of a quartz 
square cuvette in order to gain a better signal/noise ratio 
and to detect even small amounts of antibody with high 
precision, reliability and reproducibility [22, 23].  
As shown in Figure 1 and in Table 1, the tubes long 
1 cm absorbed 344.4 nanograms of Ab whereas the 
shorter ones, 0.5 cm long, absorbed 234.73 nanograms. 
The total release in 4 months was of 78.85 and 57.64 
nanograms respectively for the “long” and “short” 
tubes; in both cases approximately the 23% of the 
amount withhold was released. The tubes “long” 
adsorbed in 96 hours and released in 4 months 
respectively 1,47 times and 1,37 more Ab than the 
“short” ones. 
The experiments have been carried out at room 
temperature, in aseptic conditions and in the dark to 
reduce the fluorochrome molecules photo-bleaching.  
In order to inhibit the activity of possible residual 
proteases of the fibronectin working process, Aprotinin 
bovine lung (Sigma-Aldrich Italia; product number: 
A3428) has been used with 300 IU/ml concentration. 
Several bioengineered medical devices made of an 
inner FN mat of novel composition and of an outer 
HYAFF 11 tube have been tested as controlled delivery 
systems of monoclonal antibodies.   
In order to take into account the possibility that the 
HYAFF 11 tube outside of the FN mat could affect the 
drug release kinetics in a different way in constructs of 
different length, the experiments have been set up in 
such a way as to characterise the uptake and the release 
rates of IgG as a function of the device length. The 
release kinetic has been investigated over a period of 4 
moths to evaluate the suitability of the materials to be 
clinically employed for long term antibody therapies.   
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In order to reach these aims, 3 guides 1 cm long 
(type “Long”) and 3 guides 0.5 cm long (type “Short”) 
were used. These materials have been dipped in a 
solution of Ab at the concentration of 5 µg/ml of 
Phosphate Buffer Saline (PBS)/Aprotinin for 96 hours 
(passive absorption) and then, each one has been 
transferred in 400 µl of PBS/Aprotinin to follow the 
release kinetic.  
 
Figure 1: AL: absorption by “Long“ tubes; AS: 
absorption by “Short“ tubes; RL: release by “Long “ 
tubes; RS: release by “Short“ tubes. 
 
Table 1: amounts of antibody (in nanograms) absorbed 
and released by the two different sizes of conduits. 
In order to identify the best wavelengths at which to 
excite and to detect the emission of fluorescence, the R-
Phycoerythrin labelled Goat Anti-Mouse IgG spectra 
have been characterised in the same physical and 
chemical conditions used to carry out the experiments. 
Accordingly to the result gained the analysis were 
performed exiting the fluorochrome at 470 nm and 
detecting its emission at 580 nm.  
 
 absorption Release in solution  
  days total amount
Sampling 
time 0 1 2 6 14 27 120  
 
Short 
 
234,73 42,40 4,32 2,65 2,26 2,56 3,45 57,64 
 
Long 
 
344,4 60,74 5,67 3,37 2,30 2,67 4,10 78,85 
Long/Short 1.47 1.43 1.31 1.27 1.02 1.04 1.19 1.37 
Different standard solutions have been prepared and 
analysed (5, 3, 2, 1, 0.5, 0.25, 0.1, 0.05, 0.025, 0.01, 
0.005, 0.001 µgr/ml), and the equation of an appropriate 
interpolation function has been extrapolated.  
After 1, 2, 6, 14, 27 and 120 days, the entire volume 
of the solution in which the materials were dipped, has 
been sampled and replaced with other 400 µl of fresh 
PBS/Aprotinin. The samples have been analysed and the 
concentration of Ab has been calculated by means of the 
interpolation. The amount of IgG adsorbed by the 
constructs has been calculated as the difference between 
its initial levels inside the solutions in which the 
materials have been incubated (5 µgr/ml) and those 
found at the end of the 96 hours of incubation. 
 
As shown in Figure 2 that shows the Ab released in 
each interval of time, it is important to note that, for 
both kind of tubes, the most IgG has been released in 
the first 24 hours and only really small quantities in the 
days after.  
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Results 
 
The amount of IgG in the solutions in which the 
materials have been dipped was slightly lowered at the 
end of the period of incubation.  
According to our previous results [24] that showed 
the ability of similar FN materials to act as a depot of 
antibody, we assumed the entire amount of IgG lacking 
in solution was completely absorbed by the FN mats.  
 
Figure 2: antibody released in each interval of time. 
Moreover, as in better evidence in table 1 (Raw: 
Long/Short), in an initial phase the tubes “Long” 
released more Ab than the “Short” ones; more 
specifically in the first 24 hours they delivered 1.43 
times more Ab with a decrease of the differences 
between “long” and “short” tubes mainly after the sixth 
day.   
 
Discussion 
 
Human anti-TGFβ1 is a therapeutic antibody which 
blocks the function of human TGF-β1; it has been used 
in clinical trials for other applications and its 
biocompatibility is well assessed [25]. In this study, 
however, a standardised commercial fluorescently 
labelled IgG preparation was used, since anti-TGFβ1 
itself is structurally no different from IgG and the 
molecular weight is equivalent.  
Results from our previous work carried out on 
HYAFF 11 and different FN compositions [24], stated 
that only these last ones can act as a depot of Ab 
releasing it gradually in solution over time. According 
to this the detected IgG absorption and release dynamics 
should be then referred exclusively to the Fn mats, even 
if, it is of importance to take into account the presence 
of the HYAFF 11 that will have somehow affected the 
results.  
The 1 cm long constructs have not absorbed a 
double amount of antibody with respect to those 0.5 cm 
long but less then what would be expected on the basis 
of a linear relationship (only 1,47 times more). As 
concerns the release and in particular that of the first 24 
hours, the “long” constructs have delivered 1.43 times 
more Ab than the “short” ones encouraging the guess 
that the same starting amount of IgG would have been 
released at the same rate by tubes of different sizes. 
The release in the first hours have been rather high 
compared to that of the following ones; this could be 
explained assuming that the IgG has not been stored 
deeply inside the materials, and has therefore been 
released mostly from the surface of the FN mats and in 
smaller quantities from the inner layers of these 
materials. As concern the decrease of the “Long/Short” 
release ratio over time, it could have been due to a 
longer IgG release time from the inner regions of the FN 
mats of the “Long” constructs. Because of the presence 
of the outer HYAFF 11 tube, the lateral surfaces of the 
constructs are probably the main if not the only ones 
subject to the diffusion of the antibody in solution and, 
as the size of the constructs increases, longer times are 
probably necessary to have the IgG released through 
these regions.   
On the all, the levels of IgG released in solution 
have been rather low, mainly after the first 24 hours. In 
this respect, it is worthwhile to note that the amount of 
drug inside the constructs can affect the drug release 
kinetics [1]. The low release rates observed could be 
then related to the small amounts of antibody 
spontaneously absorbed by the materials, and to a 
higher  mass of IgG stored inside of the devices could 
probably correspond a higher concentration of antibody 
in solution and a prolonged release over time.  
 
Conclusions 
 
The results show a burst of release within the 24 
hours with a steep decrease in the following days. It is 
likely that the physiological levels of anti-TGFβ1 [26] 
needs higher amounts of Ab to be inactivated but in 
order to clearly establish if the constructs are suitable or 
not for an in vivo application to induce the anti-fibrosis 
effect further work would be required.  
More specifically, it must be better elucidated in 
which way the release rates in solution are affected by 
the amount of Ab inside of the materials; moreover the 
variability of these dynamics will have to be 
investigated as a function of the device length at 
physiological temperature. 
In order to reach these aims,  instead of carrying out 
a passive absorption, it will be of importance to directly 
load different known quantities of Ab inside different 
sized bioartificial nerve grafts.   
Moreover, in order to better understand in which 
way the Ab is released by the Fn mats and to clarify the 
role of the HYAFF 11 outer tube in affecting this 
process, fluorescence microscopy techniques will be 
used, tracing the signal of the antibody in the thickness 
of the materials over time. The use of a more stable and 
smaller Ab fluorescent tag will be taken into account, in 
order to improve the detectability of the labelled IgG 
even at lower concentrations, avoiding at the same time 
artefacts in the release kinetic and underestimation of 
release. To confirm the results of this preliminary work 
a specific anti-TGFβ1 will be used, in place of a general 
IgG; the use of the human anti-TGFβ1 itself will be 
crucial, in order not to have cross-reactions of the Ab 
with FN or other materials.  
The future expected results will be also useful to set 
up a mathematical model with which to give a first level 
estimation of the retention time of the Ab in the 
bioengineered materials of interest as a function of its 
initial amount and of the devices length. More 
specifically, more quantitative, direct measurements 
will be designed in order to calculate the diffusion 
coefficient of the human anti-TGFβ1 through the 
devices. The modelling environment will allow the 
surgeons who intend to treat peripheral nerve injures 
with such an Ab to have a reliable estimations of the 
amount of therapeutic agent to be loaded in the device, 
taking into account the length of the gap to regenerate 
and the type of materials used to set up the controlled 
delivery system. 
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